1. Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
- Author
-
Chris N. Barnes, David L. Bourdet, Srikanth Pendyala, Marie T. Borin, and Arthur Lo
- Subjects
COPD ,medicine.medical_specialty ,business.industry ,Cmax ,Renal function ,General Medicine ,medicine.disease ,Gastroenterology ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,030228 respiratory system ,Pharmacokinetics ,Internal medicine ,medicine ,Potency ,030212 general & internal medicine ,Adverse effect ,business ,Kidney disease - Abstract
Purpose Revefenacin, a long-acting muscarinic antagonist for nebulization, has been shown to improve lung function in patients with chronic obstructive pulmonary disease. Here we report pharmacokinetic (PK) and safety results from two multicenter, open-label, single-dose trials evaluating revefenacin in subjects with severe renal impairment (NCT02578082) and moderate hepatic impairment (NCT02581592). Subjects and methods The renal impairment trial enrolled subjects with normal renal function and severe renal impairment (estimated glomerular filtration rate
- Published
- 2019